Showing posts with label endometriosis. Show all posts
Showing posts with label endometriosis. Show all posts

Monday, December 3, 2018

ACOG updates its recommendations for treatment of Dysmenorrhea and Endometriosis in the Adolescent


The American College of Obstetrics and Gynecology (ACOG) has issued new guidance on diagnosing and relieving dysmenorrhea in adolescents, published in December issue of Journal Obstetrics and Gynecology.

Obstetrician and gynecologists frequently come across adolescents with dysmenorrhea in their practice due to high prevalence ranging between 50% to 90%. It is also responsible for recurrent short-term school absenteeism and reduced quality of life.

Most of the adolescents suffering from dysmenorrhea have primary dysmenorrhea–– painful menstruation in the absence of pelvic pathology.

If the physician suspects it to be primary dysmenorrhea, no pelvic examination or ultrasound is indicated in the initial evaluation. The patient should be put on empirical therapy after a careful history and physical examination.

If the patient does not respond to empirical therapy with NSAIDs and hormonal treatment in 3-6 months, she should be investigated for secondary causes or irregular treatments.

The most common cause of secondary dysmenorrhea is endometriosis, the other being obstructive anomaly of the reproductive tract (hymenal, vaginal, or Mullerian), uterine fibroids and polyps, adenomyosis, cervical stenosis, and adhesions.

Patients who do not respond to treatment for primary dysmenorrhea should be investigated for secondary causes which include pelvic examination and pelvic ultrasound. If pathology is detected, treatment of the cause is warranted.

If no pathology is seen, suspect endometriosis and consider a diagnostic laparoscopy. About 75% of adolescents and young adults with dysmenorrhea who do not respond to NSAIDs and hormonal therapy have endometriosis as the primary pathology. 

Endometriotic lesions present a different appearance in adolescents as compared to a young woman and are typically transparent or red and are challenging to diagnose.   

If a young woman is diagnosed with endometriosis, treatment consists of biopsy of the lesions along with destruction, ablation, or excision of the visible lesions at the time of initial laparoscopy. The patient should also be started on suppressive medical therapy to prevent further endometrial proliferation.

Consideration should be given to placing a levonorgestrel-releasing intrauterine system (LNG-IUS) at the of diagnostic laparoscopy to minimize the pain of insertion later. 

If patients do not respond to conservative surgical therapy and suppressive hormonal therapy, they often benefit from at least six months of gonadotropin-releasing hormone (GnRH) agonist therapy with add-back medicine.

NSAIDs are the principal medications used for pain relief in endometriosis, and there is no role of long-term opioids in the management of endometriosis, besides being used by a specialized pain management team.


Tuesday, July 24, 2018

FDA approves elagolix (Orilissa), the first and only oral treatment for endometriosis pain


The U.S. Food and Drug Administration (FDA) today approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist especially useful in the management of women with moderate to severe endometriosis pain— announced AbbVie and Neurocrine Biosciences.

Orilissa represents the first FDA approved oral treatment for endometriosis in over a decade and is expected to be available in U.S. retail pharmacies in early August 2018.


The drug is available in two oral dosages-150 mg once daily and 200 mg twice daily, taken with or without food roughly at the same time every day.

The FDA approval is supported by the results of 2 of the largest, randomized, double-blind, placebo-controlled phase 3 trials conducted to date, which evaluated nearly 1,700 women with moderate to severe endometriosis pain. Women either received 150 mg, 200 mg (952 women) or a placebo (734 women) and were evaluated at the end of 3 months.

Of the women in the treatment arm, 475 received a 150-mg daily dose, while and 477 received a 200-mg twice-daily dose.

Clinical trial results demonstrate that Orilissa significantly reduced all the 3 types of pain commonly associated with endometriosis— daily menstrual pelvic pain, non-menstrual pelvic pain, and pain with sex (p <0.001). Furthermore, women on 200 mg dose showed a significant reduction in dyspareunia as compared to placebo.

The most significant side effect observed with elagolix is dose-dependent decreases in bone mineral density; limiting the treatment to either 150 mg daily for up to 24 months or 200 mg twice daily for up to 6 months.

Bone mineral density loss is not entirely reversible on stopping the treatment. Other adverse effects are reported in 5% of patients and include hot flashes/night sweats, headache, and nausea, difficulty sleeping, an absence of periods, anxiety, joint pain, depression and mood changes.

"ORILISSA represents a significant advancement for women with endometriosis and physicians who need more options for the medical management of this disease," said Michael Severino, M.D., Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie. "The approval of ORILISSA demonstrates AbbVie's continued commitment to address serious diseases and unmet needs."



"Endometriosis is often characterized by chronic pelvic pain that can impact women's daily activities," Hugh Taylor, MD, study investigator from Yale University School of Medicine in New Haven, Connecticut, said in the release. "Women with endometriosis may undergo multiple medical treatments and surgical procedures seeking pain relief, and this approval gives physicians another option for treatment based on a woman's specific type and severity of endometriosis pain."

AbbVie is going to role in an application for the approval of elagolix in Uterine Fibroids too; the drug has already shown promising results in initial trials conducted by the drug manufacturer.


  

Thursday, May 17, 2018

News from ACOG 2018: Elagolix promises long-term safety and efficacy in the treatment of Endometriosis


Elagolix, The first oral drug Elagolix showed promising results in the treatment of three types of pain in endometriosis reports the results of a study presented at the annual clinical and scientific meeting of the annual American College of Obstetricians and Gynecologists at Austin, Texas.


Elagolix, is a gonadotropin-releasing hormone (GnRH) receptor antagonist manufactured by AbbVie, a global research and development-based biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc.

“There have been no new medications approved for a long time for systematic endometriosis and there is a huge gap because the current options are expensive, and they are often injectable drugs,” said presenter Dr. Surrey.

In this extension of an earlier phase3 trial, women with moderate to severe endometriosis-related pain who participated in the initial randomized, placebo-controlled trial were given either a 150- or 200-mg dose of Elagolix (NCT01620528).

About 569 women from 149 locations continued the treatment during the extension phase of 12 months to study the safety and efficacy of Elagolix over prolong period.

The average age of each patient group was between 31 and 34 years, and all groups were majority white, with a mean length of time from surgical diagnosis ranging from 45.5 to 56.6 months.

Patients reported a decrease in daily analgesic use by 46%-77% and improvement in dysmenorrhea and chronic pelvic pain by 49%-53% with 150 mg dose and by 82% for those at 200 mg.

Common side effect reported during the extension period was hot flashes, but they were not as severe as GnRH analogs and did not require any additional treatment. GnRH analogs are current gold standard for endometriosis and cause severe hot flashes requiring additional treatment.

The drug is also being evaluated in the treatment of uterine fibroids.

FDA is already on Elagolix and has announced April 2018 that it requires extended time to review additional information regarding the results of liver function tests provided by AbbVie in connection with its New Drug Application (NDA) for Elagolix in endometriosis-associated pain.

" We are pleased with the outcomes of the pivotal trials thus far. AbbVie will continue to pursue Elagolix as a potential new treatment for the disease's most common symptoms, including pain related to menstruation and chronic pelvic pain throughout the menstrual cycle," said Michael Severino, the chief scientific officer at AbbVie, at the time.



Tuesday, April 10, 2018

Medical management of adenomyosis: current and future therapies


The current issue of Journal of Fertility and Sterility has focused exclusively on etiology, pathophysiology, and medical and surgical treatment of adenomyosis. Adenomyosis has long been the source of controversy and its only with the recent advent of Transvaginal sonography (TVS) and MRI that its etiology and pathophysiology been better understood.

Adenomyosis is a uterine pathology in which the endometrial glands and stroma invaginate within the uterine myometrium. This ectopic endometrium induces hypertrophy and hyperplasia of the myometrium resulting in the typical ‘globular” enlargement of the uterus.

It is also now known that endometriosis and adenomyosis are two different phenotypes of the disorder characterized by impaired cellular response to ovarian hormone. This concept has to lead to the use of common treatment modalities for both the diseases.



Transvaginal sonography (TVS) and MRI are now the gold standards for diagnosing adenomyosis. Adenomyosis requires a lifelong treatment plan that depends upon patient’s age, desire for children and symptoms. Medical management is the treatment of choice for women who want to preserve fertility, while hysterectomy is preferable in older women who have completed the childbearing.

No new drug has been developed in recent years for the treatment of adenomyosis although many new drugs are under development and undergoing clinical trials.  

Medical management includes minimally invasive procedures as well as medication to treat the symptoms.

Minimally invasive surgical procedures help preserve fertility as well as reduce the pain and abnormal uterine bleeding (AUB) and include endometrial ablation and resection, laparoscopic as well as open excision of adenomyosis and MRI-guided focused ultrasound. They are offered to patients who have not responded to medical drug treatments. 

The medical treatment is mainly aimed at easing the symptoms, improving quality of life and promote fertility. The rationale behind using these drugs is based on the pathophysiology of the disease which includes aberrant response to the ovarian hormone, inflammation, and impaired apoptosis.

http://journals.sagepub.com/doi/full/10.5301/je.5000261


The class of drugs includes:

Current Medical Treatments: 


GnRH agonist: These group of drugs cause a downregulation of GnRH activity and induce a reversible state of medical menopause. Goserelin, leuprolide, and nafarelin are commonly used in clinical practice before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis.

Progestins: Drugs such as danazol, norethindrone acetate (NETA), Levonorgestrel-releasing intrauterine system (LNG-IUS), and Dienogest are mainly used because of anti-inflammatory properties to relieve pain and reduce the amount of abnormal uterine bleeding.

The Levonorgestrel-releasing intrauterine system (LNG-IUS) has been found extremely effective in reducing menorrhagia and decrease the uterine volume over a period of 12 months use.

Combined oral contraceptives (COC): They are effectively used to reduce pain and control bleeding with the additional advantage of long-term use with minimal side effects.

Future Medical treatments:

Selective estrogen receptor modulators (SERMs)
Aromatase inhibitors (AIs)
Selective progesterone receptor modulators (SPRMs)
Valproic acid
Anti-platelets therapy
NSAIDs

Thus, the medical treatment of adenomyosis comprises many current and future drugs. No double-blind, RCTs have yet been conducted in the management of adenomyosis and the drugs are solely used based on results of observational studies.



Monday, August 7, 2017

Dienogest is well tolerated and alleviates endometriosis related pain


Dienogest is highly effective and well tolerated in relieving chronic, debilitating pelvic pain of endometriosis including menstrual pain and dysparunia says results of a 12-month single-center clinical trial published ahead of print in Journal of Obstetrics and Gynecology.  This is the first new medical treatment for endometriosis related pain since a decade.

Dienogest is a synthetic oral progestogen and has recently been introduced as a new medical treatment for endometriosis in more than a decade. It is highly selective for progesterone receptor and displays strong progestational effects and moderate antigonadotrophic effects, but no androgenic, glucocorticoid or mineralocorticoid activity.

It also can be taken orally and have a long half-life for once daily administration.

Endometriosis affects 5 - 10 per cent of women of reproductive age and impacts a woman's social, professional and personal life.

This is an observational, single center trial that enrolled 132 women with a surgically confirmed diagnosis of endometriosis for more than 2 years or a clinical diagnosis of disease with endometriosis-associated pelvic pain score of at least 40 mm on a 100-mm visual analog scale (VAS).

The women were on Dienogest 2 mg daily at the time of entering into study for no more than 30 days.

Women were routinely assessed for pelvic pain at 1 (V1), 3 (V2), and 12 (V3) months of follow up.

The women reported considerable relief in pelvic pain: from an 8.9 baseline VAS to 2.4 at end of 1month treatment [V1], 1.1 at 3 months treatment [V2], and 0.8 at 12 months treatment [V3]).
Significant relief was also observed in dyspareunia, from a baseline score of 6.7 to 2.8, 1.4 and 1.4 at the end of 1,3 and 12 months respectively.

Patients also were relieved of dyschezia, from a baseline score of 5.7 to 1.2, 0.5 and 0.5 respectively at the predefined interval.

Most frequently reported side effects were changes in menstrual bleeding patterns, breast tenderness, weight gain, loss of interest in sex and vaginal dryness. But, only 21 patients discontinued the treatment because of side effects.  

In other similar clinical trials, it fared well and was not found inferior to depot leuprorelin in reducing pelvic pain and was not significantly different from intranasal buserelin and depot triptorelin in improving combined symptoms/signs scores or revised American Fertility Society (rAFS) staging scores, respectively.

Therefore , the researchers concluded, that oral dienogest offers an effective, generally well tolerated therapeutic option for the long-term treatment of endometriosis.


Wednesday, May 24, 2017

Elagolix shows promising results for long term treatment of endometriosis

Elagolix has the potential to be an important treatment option for long term medical treatment for Endometriosis, reports the results of two replicate, randomized double blind, phase III studies. The paper was presented at the 13th World Congress on Endometriosis in Vancouver, Canada and simultaneously published in the New England Journal of Medicine.

Elagolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist. It results in rapid, reversible, dose-dependent inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced ovarian production of the sex hormones, oestradiol and progesterone, while on therapy.

Medical management of Endometriosis requires treatment for extended period and physicians currently have very limited options in this regard. Treatment with gonadotropin-releasing hormone (GnRH) agonists, such as leuprolide acetate cannot be extended beyond 6 months because of osteoporosis and sever vasomotor symptoms.

These two-trial recruited 1,689 premenopausal women between the ages of 18 and 49 years, who had endometriosis and suffered from moderate to severe pain and had a z score of more than -1.5 for bone mineral density at the lumbar spine, femoral neck, or total hip. The study participants were from 151 sites in the United States and Canada from July 2012 through May 2014 and for Elaris EM-II at 187 sites on five continents from November 2013 through July 2015.

Each woman was randomly assigned to receive 150 mg of elagolix once daily (lower-dose group), 200 mg of elagolix twice daily (higher-dose group), or placebo.

The results were evaluated in terms of proportion of women who had clinical response for dysmenorrhea and non-menstrual pain after 3 months of treatment. Other relevant clinical parameters tested were dyspareunia, use of rescue NSAIDs and opioids, dyspareunia and non-menstrual pain at 6 months of treatment.

In both the trials, women showed statistically significant response in terms of dyspareunia and non-menstrual pain at 3 months of treatment as compared to placebo. The response was sustained at 6 months of treatment for these two parameters.

Women who received the higher dose of elagolix (200 mg twice daily) had significantly better results with respect to the use of rescue analgesic agents at 3 months and 6 months, dyspareunia at 3 months, and rescue opioid use at 3 months than did those receiving placebo.

Treatment with Elagolix improved the quality of life based on the 30-item Endometriosis Health Profile dimensions in both groups as compared to placebo.

Because of its hypoestrogenic effect, more than 70% women in the trial reported adverse effect including hot flushes and changes in bone mineral density and lipid levels but the frequency differed significantly between the higher and lower dose groups.

Professor Hugh Taylor, lead author of the resulting paper said, “The idea that we now have choices with regards to the extent of oestrogen suppression is attractive, as it allows us to provide a more personalised and individualised therapy.”

“With elagolix – unlike with Lupron (leuprolide acetate)– we can partially suppress oestrogen, unlike the “all or nothing” current approach,” he further added.

Elagolix is currently being investigated in uterine fibroids and endometriosis, and has been studied in over 40 clinical trials totalling more than 3,000 women. AbbVie, the makers of the drug, plans to submit a New Drug Application to the US Food and Drug Administration (FDA) for endometriosis in 2017. 

Full text of the article in NEJM can be accessed here. 




Tuesday, March 7, 2017

U.S. Preventive Services Task Force issues important update on annual pelvic exams!

Courtesy: NBC.news.

The U.S. Preventive Services Task Force (USPSTF) today released final recommendation statement and evidence summary for performing pelvic examination for screening asymptomatic adult women who are not at increased risk of any specific gynecological conditions.

The recommendations and evidence summary published online on March 7,2017 in online edition of JAMA.

The USPSTF recommends that the current evidence is insufficient to endorse or refute for routine pelvic screening in asymptomatic adult women. (I statement). This is not a recommendation against performing a routine pelvic examination, but an acknowledgement that more research is needed.   

This statement does not hold good for specific conditions like screening for cervical cancer with a “Pap” test and screening for gonorrhea and chlamydia for which screening is already advocated.

The recent recommendations are based on a systematic review conducted by USPSTF to focus on benefits, harms and accuracy of screening pelvic examination for four major conditions like ovarian cancer; bacterial vaginosis; genital herpes; and trichomoniasis.

Pelvic examination is a routine part of physical examination and in 2012 an estimated 44.2 million pelvic examinations were performed in USA. Many gynecological conditions like pelvic malignancy, infections of the genital tract and benign conditions like polyps, endometriosis and uterine fibroid are detected by pelvic examination. No studies evaluated the effectiveness of early diagnosis and treatment of screen-detected, asymptomatic gynecologic conditions compared with the diagnosis and treatment of symptomatic gynecologic conditions.

 But evidence does not favor performing a screening pelvic examination in asymptomatic women to reduce morbidity and mortality. USPSTF could find few studies that supported performing pelvic examination to reduce all-cause mortality, disease-specific morbidity or mortality, or improve quality of life.

Similarly, USPSTF found very few studies that documented the harm of screening pelvic examination. Studies reported false-positive rates for ovarian cancer, between 1.2% to 8.6%, and false-negative rates, between 0% to 100%.

The USPSTF does recognize that research gap exists in areas evaluating benefits and harms of screening pelvic examination. Future research is needed to develop risk assessment tools to identify women that can benefit from pelvic examination. These studies when done may influence the future recommendation by USPSTF.

The American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) concluded that performing screening pelvic examinations in asymptomatic, nonpregnant adult women is not recommended.

The American College of Obstetricians and Gynecologists ( ACOG)  is reviewing the USPSTF  recommendations and evidence to issue its take on the matter. It has  issued a practice advisory for screening pelvic exams today. 

Currently  ACOG recommends performing pelvic examinations annually in all patients 21 years and older.

ACOG further quotes" The Task Force recommendation does NOT apply to pregnant women, and it does NOT apply to women who present to their obstetrician-gynecologists with signs or symptoms. This recommendation applies only to asymptomatic, non-pregnant women. It is critically important for obstetrician-gynecologists to elicit accurate and complete medical, surgical, and family histories and to conduct thorough reviews of systems as part of the well-woman visit. Some women may not recognize that certain signs or symptoms are truly abnormal; these signs and symptoms may be interpreted as "normal" for them, when, in fact, they should prompt evaluation, which may include a pelvic examination."

 ACOG concluded that “the decision to perform a complete examination at the time of the periodic health examination should be a shared decision between the patient and clinician.”

USPSTF also further recognizes that the decision should be individualized according to each patient and clinical situation. The policy and insurance coverage is also taken into consideration when making a decision.  

Full text of the recommendations can be accessed here.
Full text of the evidence summary can be accessed here.

Sunday, April 3, 2016

Endocrine Disruptors linked to Endometriosis, Fibroids and rising healthcare costs!



 European Union data revealed that Women are facing a potential risk of several reproductive disorders being exposed common chemicals in the household and incurring huge public health cost.

Endocrine-disrupting compounds (EDCs) act as covert bombers of environmental toxins on human body. They are ubiquitous in our environment, entering our bodies without our knowledge-plastic linings in cans, water bottles, toys and most recently in the thermal paper used in cash register and gas pump receipts.

The recent study led by Patricia Hunt, PhD, at Washington State University was published online March 22, 2016 in the Journal of Clinical Endocrinology & Metabolism. The researchers found that exposure to controversial chemicals, like phthalates and diphenyldichlorethene (DDE), increase a woman’s likelihood of developing endometriosis and fibroids, causing reproductive health problems and incurring a whopping sum of  estimated €1.4 billion ($1.5 billion) a year in health care expenditures and lost earning potential to European Union.

Senior author Leonardo Trasande, MD, MPP, associate professor of pediatrics, environmental medicine & population health at NYU Langone Medical Center, New York, opines that this is just the tip of the iceberg of the entire female reproductive disease burden due to EDC.

Hunt and her colleagues identified other chemicals namely dioxins and polychlorinated biphenyls (PCBs), among others -- but decided to focus on phthalates and diphenyldichlorethene (DDE) as most robust set of data existed for these chemicals. 

DDE is a breakdown product of the insecticide DDT that, although banned in the United States in 1972 and in Europe starting in the 1970s still lingers in the environment and enters our body through food. The main exposure to phthalates is through eating food and drink stored in plastic containers that have phthalates.

In both cases, the epidemiological evidence was low and toxicological evidence was moderate but of all the total cases 20%–39% cases were attributed to these chemicals.
The researchers determined that 145,000 cases of endometriosis among women aged 20 to 44 years and 56,700 cases of uterine fibroids in Europe could be attributed to exposure to endocrine-disrupting chemicals.

In women 15-54 of age, the exposure to DDE was measured in 12 studies by taking a sample of cord blood. They then adapted an Intergovernmental Panel on Climate Change (IPCC) model for determining the probability of causation. The women were separated into groups according to degree of exposure, with the lowest level used as the base and than the odds ratio for developing fibroid was calculated.

The process for phthalate attributable endometriosis was similar, but the investigators relied on data from a large biomonitoring study called as DEMOnstration of a study to COordinate and Perform Human biomonitoring on a European Scale (DEMOCOPHES). Human biomonitoring (HBM) involves collecting samples from human volunteers – blood, hair, saliva or urine – and measuring the levels of indicators of chemicals uptake (known as biomarkers) that are of interest.

The authors further added that "Although it is highly appropriate to focus on these extremely important uterine tract health deficits, [polycystic ovary syndrome], infertility, and pregnancy complications also affect a considerable number of women, have major cost implications, and are increasingly linked to EDC exposures." For instance, phthalate exposure has a 40% to 69% likelihood of causing 618,000 additional assisted reproductive technology procedures each year, and a 20% to 69% likelihood of causing 42,400 new cases of childhood obesity each year.

The director of the National Institute of Environmental Health Sciences and the National Toxicology Program Linda S. Birnbaum said “Some of these chemicals, including PCBs and dioxins, have already been restricted through a treaty called the Stockholm Convention on Persistent Organic Pollutants, which went into effect in 2004.”

The current study is important because it focused on chemicals that have not been restricted, and in the case of DDE -- which persists in the environment -- are not able to be restricted.

"This study is kind of a wake-up to say endocrine disruptors impact the female reproductive system, and we have some evidence they are associated with an increase in endometriosis and fibroids and it costs a lot of money," Birnbaum said.

Not all researchers are convinced by the methodology. They say that to imply causation based on current data is highly speculative because most of the data is based on observational study and trials is human are hard to do.

Even with all the questions that remain, and few regulations in place, "there are safe and simple steps that families and women can take to reduce exposure to endocrine-disrupting chemicals," Trasande said.

"They can eat organic, reduce canned food consumption, which reduces exposure to BPA, and avoid packaged or highly processed food, which is a major route for phthalates to enter food. They can also open windows to allow chemical dust, which accumulates on the carpet and electronics, to circulate out of homes."

Although the study had several limitations: it focused on adult EDC exposure only; it relies on assumption of causation; and it focuses only on two reproductive disorders and two EDCs, it does draws attention on urgent need of  further research , government regulations and public awareness on the issue of toxic chemicals in the environment.


References:
http://press.endocrine.org/doi/10.1210/jc.2015-2873
http://saferchemicals.org/health-report/chemicals-and-our-health/reproduction/
http://www.aboutlawsuits.com/endocrine-disruptor-women-study-97423/
https://www.endocrine.org/news-room/current-press-releases/womens-health-endocrine-disruptors-diabetes-research-will-be-in-spotlight-at-endo-2016

Saturday, December 12, 2015

Achieving therapeutic balance in treatment of infertility associated with deep endometriosis!



Achieving therapeutic balance in treatment of infertility associated with deep endometriosis!

 

From Getty Images



Endometriosis is a benign gynecologic disease diagnosed in 10%-15% of the general population and as many as one third of women with endometriosis are infertile.



picture courtesy: whisperedwordsforevercaptured.blogspot.com


Asymptomatic endometriosis does not need to be treated. For patients with recurrent or constant symptoms, medical or surgical treatments can be offered.

The management of endometriosis in infertile women is somewhat controversial.

Controversy exists surrounding the issue of surgical treatment of deep, infiltrating endometriosis in infertile women.

This opinion paper by Somigliana E and Garcia-Velasco JA from  Fertil Steril. 2015; 104:764-770 addresses this latter issue.

High-quality scientific evidence to support the treatment of deep endometriosis in the context of infertility is scant because in 50%-70% of affected women, superficial endometriosis can be found in addition to deep endometriosis.

Superficial endometriosis, compared with deeply buried, infiltrating lesions, is more likely to release inflammatory cytokines that can affect reproduction. Furthermore, a sizeable proportion of cases are complicated by the presence of adenomyosis, which interferes with successful implantation. Therefore, it is difficult to draw a definite conclusion about the management of women with deep endometriosis only.

According to a systemic review and meta-analysis by Hamdan M et al- Compared with women without endometriosis, women with endometriosis undertaking in vitro fertilization and intracytoplasmic sperm injection have a similar live birth rate per woman and a similar miscarriage rate per woman and lower clinical pregnancy rate per woman and a lower mean number of oocyte retrieved per cycle.

Women with more severe disease (American Society for Reproductive Medicine III-IV) have a lower live birth rate, clinical pregnancy rate, and mean number of oocytes retrieved when compared with women with no endometriosis.

They concluded that women with and without endometriosis have comparable ART outcomes in terms of live births, whereas those with severe endometriosis have inferior outcomes. There is insufficient evidence to recommend surgery routinely before undergoing ART.

Infact, Extensive surgery for intraperitoneal and deep endometriosis in infertile women does not modify global fertility outcome but is associated with a higher complication rate.

In vitro fertilization (IVF) can be offered as an option to treat infertility in women with deep endometriosis. Conflicting results have been published about the added benefit of pre-IVF surgical excision of deep endometriosis

The opinion statement concludes that the current evidence is confounded by the lack of pure studies on deep endometriosis that are free of the negative impact of superficial endometriosis and adenomyosis.

Women who are asymptomatic or whose symptoms can be managed by medical therapy should probably go straight to IVF without any surgery beforehand.

Women whose symptoms are refractory to medical therapy or those who need immediate surgery for ureteral or bowel stenosis should undergo operative treatment before IVF, however. Surgery can also be considered for asymptomatic patients with multiple failed assisted reproduction cycles.

References

1.      Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril. 1985;43:351-352. Abstract
2.      Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261-275. Abstract
3.      Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400-412. Abstract
6.      Marcoux S, Maheux R, BĂ©rubĂ© S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med. 1997;337:217-222. Abstract
7.      Vercellini P, Pietropaolo G, De Giorgi O, Daguati R, Pasin R, Crosignani PG. Reproductive performance in infertile women with rectovaginal endometriosis: is surgery worthwhile? Am J Obstet Gynecol. 2006;195:1303-1310. Abstract
8.      Douay-Hauser N, Yazbeck C, Walker F, Luton D, Madelenat P, Koskas M. Infertile women with deep and intraperitoneal endometriosis: comparison of fertility outcome according to the extent of surgery. J Minim Invasive Gynecol. 2011;18:622-628. Abstract
9.      http://whisperedwordsforevercaptured.blogspot.com/2015/03/what-is-endometriosis_1.html

Thursday, November 12, 2015

A New Paradigm for Prevention of Ovarian Cancer



A New Paradigm for Prevention of Ovarian Cancer

This article is based on a paper by Nezhat R et al in September, 2015  issue of American Journal of Obstetrics and Gynecology.


  • It is estimated by American Cancer society that 21,290 new cases of ovarian cancer will be diagnosed in 2015, and 14,180 deaths from ovarian cancer will occur during that period.

  • The incidence of ovarian cancer varies geographically. The incidence is high in the Western world. The age-standardized rate (per 100,000 females) is only 3.8 in China, relatively lower than developed countries such the USA (8.8) and Australia (7.7).

  • A woman has a 1:70 lifetime risk of being diagnosed with ovarian cancer, the second most common gynecologic malignancy, with the highest mortality rate.

  • The majority of ovarian malignancies are epithelial in origin, and within this group the serous type is the most frequent.

  • There is currently no effective screening method available for the detection of this disease, which has an overall five-year survival rate of approximately 45%.

  • Apart from the genetics and modifiable risk factors responsible for causation of cancer, a new theory by Nezhat et al holds that serous ovarian cancer begins in the Fallopian tube from where it spreads onto the ovarian surface.

  • Nezhat and colleagues classify ovarian cancers on the basis of etiology into two groups. Type I cancers originate from various ovarian pathologies (borderline ovarian tumors, endometriomas). These cancers typically have a more favorable prognosis because they are diagnosed at an earlier stage and metastasize more slowly.

  • The more frequent type II tumors originate from the fimbriated end of the Fallopian tube and have a less favorable prognosis because they are often diagnosed at an advanced stage.

  • Two large collaborative studies have recently called attention to the role of tubal ligation on reducing the ovarian cancer risk.

  • The reduction is the greatest for endometrioid and clear-cell carcinoma, and is thought to be associated with the prevention of retrograde menstruation, ovarian seeding by endometrial cells, and inflammation.

  • The Society of Gynecologic Oncology also recommends that for women at average risk of ovarian cancer, risk-reducing salpingectomy should also be discussed and considered in patients at the time of abdominal or pelvic surgery, after completion of child-bearing.

  • The interventions called for salpingectomy at the time of hysterectomy, salpingectomy for permanent sterilization instead of tubal ligation, and referral for all patients with high-grade serous cancer for hereditary cancer counseling and genetic testing for BRCA1 and BRCA2 mutations.

  • Although still in its infancy, these 3 recommendations are projected to reduce ovarian cancer rates in this province by 40% over the next 20 years.

  • These clinical observations and the new recent evidence for the dual pathogenesis of ovarian cancer have set ground for implementing new strategies for screening and prevention programs to reduce the incidence of epithelial ovarian cancer.

  • In light of the accumulated data and observations regarding endometriosis and ovarian cancer, Nezhat R. et al propose that it is time to establish criteria for identifying and monitoring women with endometriosis for risk factors and to pursue risk-reducing medical and surgical treatment options in these women.

  • At the time of surgical diagnosis and treatment, consideration for complete resection of pelvic endometriosis, salpingectomy, oophorectomy, or hysterectomy should be individualized based on a patient’s age, desire for future fertility, and preoperative consultation with the patient.

  • These initiatives, if validated by level 1 evidence, should substantially reduce the risk of ovarian cancer as well as the total mortality risk.

  • For now, however, it seems that we may have tools in the future to combat a disease with a high mortality rate.

References:

  1. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf

  1. Pasalich M, Su D, Binns CW, Lee AH. Reproductive factors for ovarian cancer in southern Chinese women. Journal of Gynecologic Oncology. 2013;24(2):135-140. doi:10.3802/jgo.2013.24.2.135.

  1. Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2006;20:339-362.

  1. Freedman J. Ovarian cancer: current and emerging trends in detection and treatment. New York: Rosen Publishing Group; 2009.

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

  1. http://www.ajog.org/article/S0002-9378%2815%2900325-7/fulltext

  1. http://www.medscape.com/viewarticle/853973#vp_2